Skip to content
Sign in
SWC 2026 FinalistGrand Final: Main Stage

IKI Health

Physician-founded Mallorca platform letting clinicians prescribe personalised lifestyle-medicine programmes, starting with menopause.

Palma de Mallorca, Spain, EuropeHealthTech, FemTech / preventive and lifestyle medicineIbiza Tech Forum – Next Unicorn
Stage
UndeterminedAI integrated
Product
On the marketPilots / LOIs
Funding raised
$6Kdisclosed
Founded
20224 years ago
Founders
1Patricia
Global score
4.0Grade DRank 89 of 151

Overview

Mallorca-based startup building a "clinical operating system" for preventive medicine that lets healthcare professionals prescribe personalized lifestyle medicine programs (notably for menopause).

Traction

Pilots / LOIs

Professional subscriptions on sale on the website; clinical pilot with 84% satisfaction, 52% daily use, score validated on 154 patients.

Market

Digital therapeutics / preventive and lifestyle medicine

Lifestyle medicine is bought by clinicians and clinics who want structured, follow-up-able programmes for chronic and hormonal conditions, and increasingly by insurers and employers funding prevention. Menopause care is under-served and attracting FemTech investment. Professionals pay subscriptions, while payers buy when outcomes are shown. Adoption depends on clinical workflow fit and evidence.

Addressable market

2025
$9.6B
2030
$30B
+25.7% a year

Digital therapeutics / preventive and lifestyle medicine: $9.6bn in 2025, 25.7% CAGR (Global Market Insights), used as a broad proxy.

Customers

Physicians and clinics in preventive, integrative and women's health; later insurers and employers

Who signs the cheque

Clinicians and clinic owners (subscriptions); health insurers for scaled programmes

Geographies

  • Spain
  • Europe

Drivers

  • Growing attention to menopause care
  • Shift to prevention and chronic-disease management
  • Longitudinal data from apps and wearables

Headwinds

  • Almost no capital
  • Limited differentiation
  • Payer reimbursement not established

Global Market Insights values digital therapeutics at $9.6bn in 2025 and $75.4bn in 2034 (25.7% CAGR); Grand View: $32.5bn in 2030; used as a broad proxy for prescribed lifestyle medicine.

Scalability 6/10. Replicable SaaS for practitioners, but clinical content, languages and health regulations must be adapted by country.

Market source: gminsights.com

Technology

Category

Clinical SaaS / digital health

AI integratedMachine learning / predictive

Maturity

  1. R&D
  2. Prototype
  3. Pilot
  4. On the market
  5. Scaling

in market

How it works

An AI platform uses longitudinal patient data to personalise and automate the prescription of lifestyle programmes. A clinical pilot reported 84% satisfaction and 52% daily use, with a score validated on 154 patients.

Moat

Clinical validation data and physician-designed protocols give modest defensibility; the software layer is replicable.

Differentiation

Prescription by the clinician (clinical OS) rather than consumer wellness apps.

Integration points

  • Hormone and diagnostic test kits
  • Functional food and nutrition products
  • Gym and coaching platforms
  • Primary care platforms

Depends on

  • Clinical evidence
  • Data protection (GDPR, health data)
  • Integration with clinic records

Use of AI

AI uses longitudinal patient data to personalize and automate lifestyle medicine programs.

Product in detail

AI platform using longitudinal patient data to personalize and automate the prescription of lifestyle programs.

Business

Model
Professional subscriptions sold on the website.
Revenue logic
Per-professional subscription; prices not disclosed in the record.
Go-to-market
Direct to clinicians in Spain, leveraging the founder's clinic and medical network.

Next milestones

  1. Insurer or employer pilot
  2. Peer-reviewed outcome data
  3. First institutional round

Key risks

  • Undercapitalisation
  • Competition from FemTech apps
  • Slow clinician adoption

Opportunities

4 found in the network

Concrete moves for IKI Health inside the network: who to sell to, sell through, build with or raise from, each with the reasoning, the evidence and the first step.

  • Customers 1
  • Distribution 1
  • Co-development 1
  • Investors 1

Customers1

Who could buy, or sell through

Prescribe Nuhpro functional foods within IKI programmes

Nuhpro's functional foods target digestive disorders and diabetes, conditions IKI programmes address. Prescribing them inside IKI gives Nuhpro a clinical channel and IKI a nutrition component.

25%confidence

Evidence from the records

  • “Functional food brands (SWEE-THY, PRO+PRO, FREEDA) sold B2C and B2B”
  • “AI platform using longitudinal patient data to personalize and automate the prescription of lifestyle programs.”
If it works
A nutrition module with affiliate revenue for IKI and clinician-driven sales for Nuhpro.
First step
Agree a product sample programme for IKI clinicians.

Distribution1

A channel or customer base to reach together

Route exercise prescriptions to Milton-equipped gyms

Lifestyle prescriptions fail when execution is left to patients; gyms using Milton's OS can receive and track them. IKI gains adherence data, Milton gains medically referred members.

20%confidence

Evidence from the records

  • “AI agent that aggregates workouts, nutrition and wearable data and automatically triggers operational actions.”
  • “clinical pilot with 84% satisfaction, 52% daily use”
If it works
A clinic-to-gym referral loop improving adherence.
First step
Map the data fields needed to send an exercise prescription into Milton.

Co-development1

An integration or joint product

Combine Hormony's saliva hormone kit with IKI prescriptions

Menopause programmes need objective hormone data, which Hormony sells as a saliva kit; IKI turns data into clinician-prescribed programmes. A combined test-to-programme offer is stronger for both and opens cross-distribution between Spain and Hormony's markets.

40%confidence

Evidence from the records

  • “prescribe personalized lifestyle medicine programs (notably for menopause)”
  • “Saliva hormone test kit combined with digital tools and AI to track and interpret symptoms.”
  • “Kit sold in Hong Kong through the Mannings pharmacy chain.”
If it works
A bundled menopause pathway and entry for IKI into Spanish-speaking Latin America via Hormony.
First step
Propose a pilot where 50 IKI patients use the Hormony kit, with shared outcome reporting.

Investors1

A fund whose thesis fits

Pitch Mutua Ventures on prevention for an insurer

Mutua Ventures is the Spanish insurer-backed CVC investing in HealthTech in Spain and Europe and backed network member Legit.Health. A prevention platform with clinical data matches an insurer's interest in reducing claims.

40%confidence

Evidence from the records

  • “HealthTech”
  • “Physician founder”
  • “Pilot data”
If it works
Capital plus an insurer pilot channel.
First step
Ask Legit.Health's founders to introduce IKI to Mutua Ventures.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai.

Investors that fit

Corporate venture arm of Spanish insurer Mutua Madrileña, investing in health and fintech; led Legit.Health's 2024 round.

Spanish preventive/lifestyle femtech — prevention lowers insurer costs.

50%confidence

Evidence from the records

  • “"Spain","Europe"”
  • “FemTech / preventive and lifestyle medicine”
  • “Professional subscriptions on sale on the website”
Intro path
Founder-to-founder intro via Legit.Health (network portfolio company of Mutua Ventures (Mutua Madrileña)).
First step
Pitch an insurer prevention pilot via Legit.Health.

Spanish healthcare corporate investor whose only known venture deal is dermatology AI company Legit.Health.

Spanish femtech / preventive lifestyle medicine — home market and HealthTech; very early (≈$6K raised).

45%confidence

Evidence from the records

  • “"HealthTech"”
  • “FemTech / preventive and lifestyle medicine”
  • “Professional subscriptions on sale on the website”
Intro path
Founder-to-founder intro via Legit.Health (network portfolio company of Grupo Ribera).
First step
Request a pilot conversation via Legit.Health's founders.

Telefónica's corporate venture and open-innovation hub (€9.3M in 37 startups in 2024) for Europe and Latin America.

Spanish lifestyle-medicine clinical OS: health, Spain, alongside Legit.Health; Telefónica synergy less obvious.

30%confidence

Evidence from the records

  • “FemTech / preventive and lifestyle medicine”
  • “Spain”
Intro path
Legit.Health founders (Spanish health AI peers).
First step
Ask Legit.Health for an intro to Wayra Spain.

Boston fund investing only in PharmStars accelerator graduates: pharma-ready digital health, first 12 deals in rare-disease digital health.

Clinical OS for lifestyle medicine (menopause) with a validated score; pharma fit is indirect (women's-health drug makers).

30%confidence

Evidence from the records

  • “FemTech / preventive and lifestyle medicine”
  • “score validated on 154 patients”
First step
Test pharma interest in iKi's menopause programme data before applying.

Spain-based investor with an empty profile; its only recorded network deal is Argentine clinical-data marketplace Cromodata's pre-seed.

Mallorca clinical OS for lifestyle medicine with validated pilots: Spanish digital health, consistent with the one observed health deal.

30%confidence

Evidence from the records

  • “Mallorca-based startup building a "clinical operating system" for preventive medicine”
  • “Spain”
Intro path
Cromodata founders (Sancus portfolio).
First step
Ask Cromodata about Sancus's process, then pitch iKi.

Portuguese angel vehicle backing Portuguese AI startups at pre-seed, targeting a 20-company portfolio.

Spanish preventive-medicine FemTech with AI and a validated clinical pilot: Iberian AI health close to the Lampsy pattern, but not Portuguese.

20%confidence

Evidence from the records

  • “FemTech / preventive and lifestyle medicine”
  • “score validated on 154 patients”
Intro path
Lampsy Health (Angels Way portfolio, network peer)
First step
Only pursue if IKI plans a Portuguese entity or launch.

Portuguese foundation of insurer Ageas that took part in Lampsy Health's pre-seed (seizure detection).

Spanish preventive-medicine FemTech with a validated score: Iberian health impact.

20%confidence

Evidence from the records

  • “FemTech / preventive and lifestyle medicine”
  • “score validated on 154 patients”
Intro path
Lampsy Health (Ageas portfolio)
First step
Explore Portuguese launch via Lampsy.

Vienna's university high-tech incubator (University of Vienna, TU Wien) running SCALEup, Health Hub Vienna and other programmes for Austrian deep tech.

Spanish preventive health — HealthTech fit; Austrian entity needed.

20%confidence

Evidence from the records

  • “"HealthTech"”
  • “FemTech / preventive and lifestyle medicine”
  • “Professional subscriptions on sale on the website”
Intro path
Founder-to-founder intro via Deepentix (network portfolio company of INiTS).
First step
Low priority.

Investment analysis

4.0D

Grade D

Rank 89 of 151

Disruption4.0/10
Business model3.0/10
Market5.0/10
Risk(lower is better)7.0/10

Global score = mean of disruption, model, market and (11 − risk). Last updated 21 Nov 2026.

Too early and not differentiated enough.

Disruption

4/10

Prescribed lifestyle medicine platform: a known category.

Business model

3/10

Subscriptions on sale and clinical pilot on 154 patients; revenue not published.

Market

5/10

Score 5/10: TAM $9.6bn → base 5; scalability 6/10 (0); no commercial presence in ≥2 countries yet (0).

Risk

7/10

Lower is better

High risk: almost no funding, weak differentiation.

Strengths

  • Physician founder
  • Pilot data

Risks

  • Almost no capital
  • Limited differentiation

Funding

$6K, disclosed
  1. 2025-2026

    prize (EmprendeXXI)€6,000

    EmprendeXXI prize (CaixaBank / ENISA)

  2. non précisée

    possible public participative loan (not confirmed)not disclosed

    ENISA (logo on the website, type not specified)

  3. non précisée

    investment (amount not disclosed)not disclosed

    Max Ventures (El Referente investor profile)

Amount used in the study. Only the €6,000 EmprendeXXI prize is quantified.

Note. no public funding round found (only the €6,000 EmprendeXXI prize is documented; ENISA logo on the website with no amount or type specified)

Added an investor cited by El Referente (Max Ventures, no date or amount). No published 2025-2026 funding round found; founding in 2022 confirmed (village.ai).

Team

  • Patricia Puiggròs

    Founder & CEO

    Physician (anesthesiology, chronic pain) with 20+ years of experience; created an integrative sports medicine clinic in Palma; founded IKI Health in 2022.

Sources

Regional final
Ibiza Tech Forum – Next Unicorn
Identification confidence
high
  1. 1ecosistemastartup.com/?p=112561
  2. 2elreferente.es/?p=158906
  3. 3village.ai/company/iki-health-group
  4. 4iki.health/
  5. 5elreferente.es/?p=136670

From the open study Startup World Cup 2026 by TIBOK, based on public sources, verified in November 2026. Scores are an analyst's judgment on an explicit grid, not the jury's.

Wall

Wall

No posts yet